JNCE - Jounce Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
185.75M
Enterprise Value 3
8.46M
Trailing P/E
2.44
Forward P/E 1
-2.65
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
1.11
Price/Book (mrq)
0.97
Enterprise Value/Revenue 3
0.05
Enterprise Value/EBITDA 6
0.11

Trading Information

Stock Price History

Beta (3Y Monthly) 3.51
52-Week Change 320.24%
S&P500 52-Week Change 314.45%
52 Week High 37.35
52 Week Low 32.66
50-Day Moving Average 33.58
200-Day Moving Average 34.22

Share Statistics

Avg Vol (3 month) 3123.17k
Avg Vol (10 day) 3293.11k
Shares Outstanding 533.23M
Float 16.13M
% Held by Insiders 113.32%
% Held by Institutions 179.73%
Shares Short (Oct 31, 2019) 4421.16k
Short Ratio (Oct 31, 2019) 44.04
Short % of Float (Oct 31, 2019) 42.63%
Short % of Shares Outstanding (Oct 31, 2019) 41.27%
Shares Short (prior month Sep 30, 2019) 4302.02k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 46.11%
Operating Margin (ttm)43.58%

Management Effectiveness

Return on Assets (ttm)20.04%
Return on Equity (ttm)52.54%

Income Statement

Revenue (ttm)167.97M
Revenue Per Share (ttm)5.09
Quarterly Revenue Growth (yoy)722.20%
Gross Profit (ttm)34.31M
EBITDA 77.07M
Net Income Avi to Common (ttm)77.45M
Diluted EPS (ttm)2.29
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)175.8M
Total Cash Per Share (mrq)5.29
Total Debt (mrq)20.45M
Total Debt/Equity (mrq)10.69
Current Ratio (mrq)13.60
Book Value Per Share (mrq)5.76

Cash Flow Statement

Operating Cash Flow (ttm)-30.97M
Levered Free Cash Flow (ttm)-3.72M